Benefit of Augmented Reality Mirror Therapy in Addition to Conventional Management in Complex Regional Pain Syndrome of the Upper Extremity
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Mar 24, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for people with Complex Regional Pain Syndrome (CRPS) affecting the arm. CRPS is a condition that causes severe pain and other changes in the affected area, such as swelling and sensitivity. The trial is looking at how well augmented reality mirror therapy (ARMT) works when combined with traditional treatments like physiotherapy and occupational therapy. ARMT uses a special device to create a virtual environment that helps patients with pain management and recovery.
To participate in the trial, individuals must be between the ages of 18 and 75, have been diagnosed with CRPS in the upper limb for at least three months, and be receiving treatment at a specific medical center. Participants will need to provide consent and be part of a health insurance plan. It's important to note that individuals with certain conditions, such as significant visual impairment or cognitive disorders, may not be eligible. Those who join the trial can expect to receive a combination of ARMT and standard rehabilitation therapies, and the study aims to see if this new approach helps improve their symptoms more effectively than traditional treatments alone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient must have given their free and informed consent and signed the consent form
- • The patient must be a member or beneficiary of a health insurance plan
- • Patient with CRPS of the upper limb according to the Budapest criteria.
- • Patient newly treated at the Centre d'Evaluation et de Traitement de la Douleur of the CHU of Nîmes.
- • Patient with a diagnosis of CRPS for more than 3 months
- Exclusion Criteria:
- • The subject is participating in a therapeutic study, or is in a period of exclusion determined by a previous study
- • The subject unable to express consent
- • It is impossible to give the subject informed information
- • The patient is under safeguard of justice or state guardianship
- • Patient is pregnant, parturient or breastfeeding
- • Patient with medically significant visual impairment that is incompatible with the practice of ARMT
- • Patient with CRPS secondary to a stroke
- • Patient with cognitive disorders (Montreal Cognitive Assessment scale less than 26)
- • Patient with Unilateral Spatial Negligence according to the Bell's test
- • Patient with arthrodesis of one of the joints of the upper limbs.
- • Patient with an unhealed fracture of one of the upper limbs
About Centre Hospitalier Universitaire De Nīmes
The Centre Hospitalier Universitaire de Nîmes (CHU Nîmes) is a leading academic medical center located in Nîmes, France, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, CHU Nîmes collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous studies aimed at improving treatment outcomes and enhancing medical knowledge across various specialties. With a strong commitment to ethical standards and patient safety, CHU Nîmes fosters a research environment that encourages scientific excellence and contributes to the development of new therapies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nîmes, , France
Patients applied
Trial Officials
Arnaud DUPEYRON
Principal Investigator
CHU de Nimes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials